) recently announced that the US district court for the southern
district of N.Y. has issued a favorable final judgment in a
patent infringement case with Sunovion Pharmaceuticals.
The final verdict was in line with the decision issued by the
Court of Appeals for the Federal Circuit. According to the order
issued by the court, Mylan's five patents related to its chronic
obstructive pulmonary disease drug Perforomist stand as valid and
enforceable and are infringed by Sunovion's Brovana. Brovana is
approved for controlling the symptoms of COPD, including chronic
bronchitis and emphysema. Both Brovana and Perforomist are
long-acting beta-2 agonists.
In 2012, Mylan settled its patent dispute with Sunovion Pharma
pertaining to Brovana. Sunovion recognized that Brovana infringed
two of Mylan's patents, which are valid till Jun 22, 2021.
Following the currently issued favorable ruling, Mylan's seven
patents pertaining to Perforomist stand as valid and enforceable
and are infringed by Sunovion's Brovana.
We note that the Perforomist inhalation solution is marketed by
the Mylan Specialty segment. The drug performed well in the first
quarter of 2013. The most significant product in this segment is
EpiPen auto-injector, which is used to treat severe allergic
The bulk of the revenues come from the company's generic
division. The generics business has been consistently
performing well. Mylan's generic unit has seen quite a few
launches over the past few months. One of the important recent
launches includes the company's generic version of
) erectile dysfunction drug Viagra.
Dr. Reddy's Laboratories Ltd.
) too has been making multiple generic launches over the past few
Mylan carries a Zacks Rank #2 (Buy).
Simcere Pharmaceutical Group
) appears to be equally attractive.
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis
SIMCERE PHARMAC (SCR): Free Stock Analysis
To read this article on Zacks.com click here.